CORMEDIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.05 USD | -1.37% |
|
-4.72% | +34.31% |
| May. 09 | Transcript : CorMedix Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 278M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | -1M | EV / Sales 2024 * | 7.89 x |
| Net cash position 2024 * | 78.97M | Net cash position 2025 * | 67.68M | EV / Sales 2025 * | 2.56 x |
| P/E ratio 2024 * |
-7.21
x | P/E ratio 2025 * |
-106
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on CorMedix Inc.
More recommendations
More press releases
| 1 day | -1.37% | ||
| 1 week | -4.72% | ||
| Current month | -3.90% | ||
| 1 month | -4.36% | ||
| 3 months | +53.50% | ||
| 6 months | +33.60% | ||
| Current year | +34.31% |
1 week
4.94
5.42
1 month
4.946.08
Current year
2.897.00
1 year
2.577.00
3 years
2.578.38
5 years
2.1618.80
10 years
0.8652.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.49% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 5.05 | -1.37% | 693,902 |
| 24-05-17 | 5.12 | -1.54% | 475,555 |
| 24-05-16 | 5.2 | -0.95% | 478,733 |
| 24-05-15 | 5.25 | -1.50% | 509,921 |
| 24-05-14 | 5.33 | +0.57% | 468,004 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.05
USD
Average target price
13
USD
Spread / Average Target
+157.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.31% | 278M | |
| +15.58% | 78.65B | |
| +9.56% | 8.94B | |
| -10.76% | 5.16B | |
| +54.31% | 4.85B | |
| +11.19% | 4.19B | |
| -22.37% | 2.32B | |
| +12.49% | 2.29B | |
| -30.09% | 2.19B | |
| +20.63% | 2.19B |
- Stock Market
- Equities
- CRMD Stock